EUVIMEDEUVIMED entdecken
Crossref

A Model‐Based Trial Design With a Randomization Scheme Considering Pharmacokinetics Exposure for Dose Optimization in Oncology

Jun Zhang, Kentaro Takeda iD, Masato Takeuchi, Kanji Komatsu, Jing Zhu, Yusuke Yamaguchi iD

Pharmaceutical Statistics · 2025

DOI: 10.1002/pst.2454 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Statistics, 2025. Verfasst von Jun Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Data Science, Astellas Pharma China, Beijing, China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Research Design, Randomized Controlled Trials as Topic, Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The primary purpose of an oncology dose‐finding trial for novel anticancer agents has been shifting from determining the maximum tolerated dose to identifying an optimal dose (OD) that is tolerable and therapeutically beneficial for subjects in subsequent clinical trials. In 2022, the FDA Oncology Center of Excellence initiated Project Optimus to reform the paradigm of dose optimization and dose selection in oncology drug development and issued a draft guidance. The guidance suggests that dose‐finding trials include randomized dose–response cohorts of multiple doses and incorporate information on pharmacokinetics (PK) in addition to safety and efficacy data to select the OD. Furthermore, PK information could be a quick alternative to efficacy data to predict the minimum efficacious dose and decide the dose assignment. This article proposes a model‐based trial design for dose optimization with a randomization scheme based on PK outcomes in oncology. A simulation study shows that the proposed design has advantages compared to the other designs in the percentage of correct OD selection and the average number of patients assigned to OD in various realistic settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsResearch DesignRandomized Controlled Trials as TopicNeoplasmsModels, BiologicalHumansDose-Response Relationship, DrugMaximum Tolerated DoseComputer SimulationModels, StatisticalDrug Development

Stichwörter der Autor:innen

Bayesian adaptive dose‐finding designPhase I‐II clinical trial designdose optimizationmodel‐based designpharmacokinetics

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Data Science, Astellas Pharma China, Beijing, China.
  • Data Science, Astellas Pharma Global Development, Inc., Northbrook, Illinois, USA.
  • Early Development New Technologies, Astellas Pharma Inc, Tokyo, Japan.

ORCID-Profile: Kentaro Takeda, Yusuke Yamaguchi

Zitieren

APA

Zhang, J., Takeda, K., Takeuchi, M., Komatsu, K., Zhu, J., & Yamaguchi, Y. (2025). A Model‐Based Trial Design With a Randomization Scheme Considering Pharmacokinetics Exposure for Dose Optimization in Oncology. Pharmaceutical Statistics. https://doi.org/10.1002/pst.2454

Vancouver

Zhang J, Takeda K, Takeuchi M, Komatsu K, Zhu J, Yamaguchi Y. A Model‐Based Trial Design With a Randomization Scheme Considering Pharmacokinetics Exposure for Dose Optimization in Oncology. Pharmaceutical Statistics. 2025. doi:10.1002/pst.2454

BibTeX
@article{Zhang2025,
  author = {Zhang, Jun and Takeda, Kentaro and Takeuchi, Masato and Komatsu, Kanji and Zhu, Jing and Yamaguchi, Yusuke},
  title = {A Model‐Based Trial Design With a Randomization Scheme Considering Pharmacokinetics Exposure for Dose Optimization in Oncology},
  journal = {Pharmaceutical Statistics},
  year = {2025},
  doi = {10.1002/pst.2454}
}
Kostenlos starten →